Try a new search

Format these results:

Searched for:



Total Results:


Improvement of Symptoms and Quality of Life After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Elderly Patients

Zhao, Shuai; Wang, Jiayi; Chen, Yan; Wang, Wei; Hu, Wentao; Zou, Yiming; Zhu, Boda; Yang, Li; Chen, Genrui; Yu, Tiantong; Han, Peng; Ma, Bingqi; Wang, Huan; Xia, Chenhai; Wang, Rutao; Tan, Zhijun; Zhai, Zhongjie; Li, Rong; Gao, Haokao; Lian, Kun; Li, Chengxiang
Background Data regarding the impact of successful chronic total occlusion treated with percutaneous coronary intervention (CTO-PCI) on symptoms and quality of life (QOL) in elderly patients (≥75 years) are unknown. This prospective study aimed to assess whether successful CTO-PCI could improve the symptoms and QOL in elderly patients (≥75 years). Methods and Results Consecutive patients who underwent elective CTO-PCI were prospectively enrolled and subdivided into 3 groups based on age: age<65 years, 65 years≤age<75 years, and age≥75 years. The primary outcomes included symptoms, as assessed with the New York Heart Association functional class and Seattle Angina Questionnaire, and QOL, as assessed with the 12-Item Short-Form Health Survey questionnaire, at baseline, 1 month, and 1 year after successful CTO-PCI. Of 1076 patients with CTO, 101 were age≥75 years (9.39%). Hemoglobin, estimated glomerular filtration rate, and left ventricular ejection fraction levels all decreased with increasing age, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) increased. The proportion of dyspnea and coronary lesions, including multivessel disease, multi-CTO lesion, and calcification were higher in elderly patients. Procedural success rate, intraprocedural complications, and in-hospital major adverse cardiac events were not statistically different in the 3 groups. Importantly, symptoms, including dyspnea and angina, were markedly improved regardless of age at 1-month and 1-year follow-up (P<0.05). Likewise, successful CTO-PCI significantly improved QOL at 1-month and 1-year follow-up (P<0.01). Additionally, the incidence of major adverse cardiac events and all-cause mortality at 1-month and 1-year follow-up was not statistically different in the 3 groups. Conclusions Successful PCI was beneficial and feasible to improve symptoms and QOL in patients ≥75 years of age with CTO.
PMID: 37026557
ISSN: 2047-9980
CID: 5506762

Use of dual genomic sequencing to screen mitochondrial diseases in pediatrics: a retrospective analysis

Wu, Teng-Hui; Peng, Jing; Yang, Li; Chen, Yan-Hui; Lu, Xiu-Lan; Huang, Jiao-Tian; You, Jie-Yu; Ou-Yang, Wen-Xian; Sun, Yue-Yu; Xue, Yi-Nan; Mao, Xiao; Yan, Hui-Ming; Ren, Rong-Na; Xie, Jing; Chen, Zhi-Heng; Zhang, Victor-Wei; Lyu, Gui-Zhen; He, Fang
Mitochondrial diseases (MDs) were a large group multisystem disorders, attributable in part to the dual genomic control. The advent of massively sequencing has improved diagnostic rates and speed, and was increasingly being used as a first-line diagnostic test. Paediatric patients (aged < 18 years) who underwent dual genomic sequencing were enrolled in this retrospective multicentre study. We evaluated the mitochondrial disease criteria (MDC) and molecular diagnostic yield of dual genomic sequencing. Causative variants were identified in 177 out of 503 (35.2%) patients using dual genomic sequencing. Forty-six patients (9.1%) had mitochondria-related variants, including 25 patients with nuclear DNA (nDNA) variants, 15 with mitochondrial DNA (mtDNA) variants, and six with dual genomic variants (MT-ND6 and POLG; MT-ND5 and RARS2; MT-TL1 and NARS2; MT-CO2 and NDUFS1; MT-CYB and SMARCA2; and CHRNA4 and MT-CO3). Based on the MDC, 15.2% of the patients with mitochondria-related variants were classified as "unlikely to have mitochondrial disorder". Moreover, 4.5% of the patients with non-mitochondria-related variants and 1.43% with negative genetic tests, were classified as "probably having mitochondrial disorder". Dual genomic sequencing in suspected MDs provided a more comprehensive and accurate diagnosis for pediatric patients, especially for patients with dual genomic variants.
PMID: 36918699
ISSN: 2045-2322
CID: 5454002

Benefits of successful percutaneous coronary intervention in chronic total occlusion patients with diabetes

Zhao, Shuai; Chen, Yan; Wang, Qingyi; Zhu, Boda; Wei, Zhihong; Wang, Ziwei; Wang, Jiayi; Zou, Yiming; Hu, Wentao; Liu, Cheng; Yu, Tiantong; Han, Peng; Yang, Li; Wang, Huan; Xia, Chenhai; Liu, Qiling; Wang, Wei; Gao, Haokao; Li, Chengxiang; Lian, Kun
BACKGROUND:Diabetes was commonly seen in chronic total occlusion (CTO) patients but data regarding the impact of successful percutaneous coronary intervention (PCI) on clinical outcome of CTO patients with diabetes was controversial. And importantly, no studies have compared quality of life (QOL) after CTO-PCI in patients with and without diabetes. METHODS:Consecutive patients undergoing elective CTO-PCI were prospectively enrolled from Apr. 2018 to May 2021. Patients were subdivided into 2 groups: Diabetes and No Diabetes. Detailed baseline characteristics, assessment of symptoms and QOL, angiographic and procedural details, in-hospital complications, and 1 month and 1 year follow-up data were collected. These data were analyzed accordingly for risk predictors of clinical outcome in patients who have diabetes and received successful CTO-PCI. RESULTS:A total of 1076 patients underwent CTO-PCI attempts. Diabetes was present in 374 (34.76%) patients, who had more hypertension, previous PCI and stroke. Regarding the coronary lesions, diabetic patients suffered more LCX lesion, multivessel disease, number of lesions per patient, blunt stump, calcification and higher J-CTO score (p < 0.05). In-hospital major adverse cardiac event (MACE) (4.13% vs. 5.35%; p = 0.362) was similar in the two groups. At 1 month and 1 year follow-up after successful CTO-PCI, the incidence of MACE and all-cause mortality were also similar in the two groups (p > 0.05). Number of lesions per patient was an independent risk factor of MACE and all-cause mortality (p < 0.001) 1 year after successful CTO-PCI. Symptom and QOL were markedly improved regardless of diabetes both at 1 month and 1 year follow-up, and importantly, patients with diabetes showed similar degrees of improvement to those without diabetes (P > 0.05). CONCLUSIONS:Successful CTO-PCI could represent an effective strategy improving clinical outcome, symptoms and QOL in CTO patients with diabetes.
PMID: 36471410
ISSN: 1475-2840
CID: 5400002

Altered corticostriatal synchronization associated with compulsive-like behavior in APP/PS1 mice

Peng, Yi-Gang; Cai, Ping-Jing; Hu, Jian-Hang; Jiang, Jin-Xiang; Zhang, Jia-Jia; Liu, Ke-Fang; Yang, Li; Long, Cheng
Mild behavioral impairment (MBI), which can include compulsive behavior, is an early sign of Alzheimer's disease (AD), but its underlying neural mechanisms remain unclear. Here, we show that 3-5-month-old APP/PS1 mice display obsessive-compulsive disorder (OCD)-like behavior. The number of parvalbumin-positive (PV) interneurons and level of high gamma (γhigh) oscillation are significantly decreased in the striatum of AD mice. This is accompanied by enhanced β-γhigh coupling and firing rates of putative striatal projection neurons (SPNs), indicating decorrelation between PV interneurons and SPNs. Local field potentials (LFPs) simultaneously recorded in prefrontal cortex (PFC) and striatum (Str) demonstrate a decrease in γhigh-band coherent activity and spike-field coherence in corticostriatal circuits of APP/PS1 mice. Furthermore, levels of GABAB receptor (GABABR), but not GABAA receptor (GABAAR), and glutamatergic receptors, were markedly reduced, in line with presymptomatic AD-related behavioral changes. These findings suggest that MBI occurs as early as 3-5 months in APP/PS1 mice and that altered corticostriatal synchronization may play a role in mediating the behavioral phenotypes observed.
PMID: 34242631
ISSN: 1090-2430
CID: 4976752

The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder

Faraone, Stephen V; Banaschewski, Tobias; Coghill, David; Zheng, Yi; Biederman, Joseph; Bellgrove, Mark A; Newcorn, Jeffrey H; Gignac, Martin; Al Saud, Nouf M; Manor, Iris; Rohde, Luis Augusto; Yang, Li; Cortese, Samuele; Almagor, Doron; Stein, Mark A; Albatti, Turki H; Aljoudi, Haya F; Alqahtani, Mohammed M J; Asherson, Philip; Atwoli, Lukoye; Bölte, Sven; Buitelaar, Jan K; Crunelle, Cleo L; Daley, David; Dalsgaard, Søren; Döepfner, Manfred; Espinet, Stacey; Fitzgerald, Michael; Franke, Barbara; Haavik, Jan; Hartman, Catharina A; Hartung, Cynthia M; Hinshaw, Stephen P; Hoekstra, Pieter J; Hollis, Chris; Kollins, Scott H; Sandra Kooij, J J; Kuntsi, Jonna; Larsson, Henrik; Li, Tingyu; Liu, Jing; Merzon, Eugene; Mattingly, Gregory; Mattos, Paulo; McCarthy, Suzanne; Mikami, Amori Yee; Molina, Brooke S G; Nigg, Joel T; Purper-Ouakil, Diane; Omigbodun, Olayinka O; Polanczyk, Guilherme V; Pollak, Yehuda; Poulton, Alison S; Rajkumar, Ravi Philip; Reding, Andrew; Reif, Andreas; Rubia, Katya; Rucklidge, Julia; Romanos, Marcel; Ramos-Quiroga, J Antoni; Schellekens, Arnt; Scheres, Anouk; Schoeman, Renata; Schweitzer, Julie B; Shah, Henal; Solanto, Mary V; Sonuga-Barke, Edmund; Soutullo, César; Steinhausen, Hans-Christoph; Swanson, James M; Thapar, Anita; Tripp, Gail; van de Glind, Geurt; Brink, Wim van den; Van der Oord, Saskia; Venter, Andre; Vitiello, Benedetto; Walitza, Susanne; Wang, Yufeng
BACKGROUND:Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. METHODS:We reviewed studies with more than 2,000 participants or meta-analyses from five or more studies or 2,000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For network meta-analyses we required comparison adjusted funnel plots. We excluded treatment studies with waiting-list or treatment as usual controls. From this literature, we extracted evidence-based assertions about the disorder. RESULTS:We generated 208 empirically supported statements about ADHD. The status of the included statements as empirically supported is approved by 79 authors from 27 countries and 6 continents. The contents of the manuscript are endorsed by 362 people who have read this document and agree with its contents. CONCLUSIONS:Many findings in ADHD are supported by meta-analysis. These allow for firm statements about the nature, course, outcome causes, and treatments for disorders that are useful for reducing misconceptions and stigma.
PMID: 33549739
ISSN: 1873-7528
CID: 4779222

Minocycline inhibits sleep deprivation-induced aberrant microglial activation and Keap1-Nrf2 expression in mouse hippocampus

Ahmed, Adeel; Misrani, Afzal; Tabassum, Sidra; Yang, Li; Long, Cheng
Sleep deprivation (SD) is a hallmark of modern society and associated with many neuropsychiatric disorders, including depression and anxiety. However, the cellular and molecular mechanisms underlying SD-associated depression and anxiety remain elusive. Does the neuroinflammation play a role in mediating the effects of SD? In this study, we investigated SD-induced cellular and molecular alterations in the hippocampus and asked whether treatment with an anti-inflammatory drug, minocycline, could attenuate these alterations. We found that SD animals exhibit activated microglia and decreased levels of Keap1 and Nrf2 (antioxidant and anti-inflammatory factors) in the hippocampus. In vivo local field potential recordings show decreased theta and beta oscillations, but increased high gamma oscillations, as a result of SD. Behavioral analysis revealed increased immobility time in the forced swim and tail suspension tests, and decreased sucrose intake in SD mice, all indicative of depressive-like behavior. Moreover, open field test and elevated plus maze test results indicated that SD increases anxiety-like behavior. Interestingly, treatment with the microglial modulator minocycline prevented SD-induced microglial activation, restored Keap1 and Nrf2 levels, normalized neuronal oscillations, and alleviated depressive-like and anxiety-like behavior. The present study reveals that microglial activation and Keap1-Nrf2 signaling play a crucial role in SD-induced behavioral alteration, and that minocycline treatment has a protective effect on these alterations.
PMID: 34087360
ISSN: 1873-2747
CID: 4908642

Mitochondrial Deficits With Neural and Social Damage in Early-Stage Alzheimer's Disease Model Mice

Misrani, Afzal; Tabassum, Sidra; Huo, Qingwei; Tabassum, Sumaiya; Jiang, Jinxiang; Ahmed, Adeel; Chen, Xiangmao; Zhou, Jianwen; Zhang, Jiajia; Liu, Sha; Feng, Xiaoyi; Long, Cheng; Yang, Li
Alzheimer's disease (AD) is the most common neurodegenerative disorder worldwide. Mitochondrial dysfunction is thought to be an early event in the onset and progression of AD; however, the precise underlying mechanisms remain unclear. In this study, we investigated mitochondrial proteins involved in organelle dynamics, morphology and energy production in the medial prefrontal cortex (mPFC) and hippocampus (HIPP) of young (1∼2 months), adult (4∼5 months) and aged (9∼10, 12∼18 months) APP/PS1 mice. We observed increased levels of mitochondrial fission protein, Drp1, and decreased levels of ATP synthase subunit, ATP5A, leading to abnormal mitochondrial morphology, increased oxidative stress, glial activation, apoptosis, and altered neuronal morphology as early as 4∼5 months of age in APP/PS1 mice. Electrophysiological recordings revealed abnormal miniature excitatory postsynaptic current in the mPFC together with a minor connectivity change between the mPFC and HIPP, correlating with social deficits. These results suggest that abnormal mitochondrial dynamics, which worsen with disease progression, could be a biomarker of early-stage AD. Therapeutic interventions that improve mitochondrial function thus represent a promising approach for slowing the progression or delaying the onset of AD.
PMID: 34955809
ISSN: 1663-4365
CID: 5100072

Disrupted prefrontal neuronal oscillations and morphology induced by sleep deprivation in young APP/PS1 transgenic AD mice

Tabassum, Sidra; Misrani, Afzal; Tabassum, Sumaiya; Ahmed, Adeel; Yang, Li; Long, Cheng
Emerging evidence suggests that sleep deprivation (SD) is a public health epidemic and increase the risk of Alzheimer's disease (AD) progression. However, the underlying mechanisms remain to be fully investigated. In this study, we investigate the impact of 72 h SD on the prefrontal cortex (PFC) of 3∼4-months-old APP/PS1 transgenic AD mice - at an age before the onset of plaque formation and memory decline. Our results reveal that SD alters delta, theta and high-gamma oscillations in the PFC, accompanied by increased levels of excitatory postsynaptic signaling (NMDAR, GluR1, and CaMKII) in AD mice. SD also caused alteration in the dendritic length and dendritic branches of PFC pyramidal neurons, accompanied by a reduction in neuroprotective agent CREB. This study suggests that failure to acquire adequate sleep could trigger an early electrophysiological, molecular, and morphological alteration in the PFC of AD mice. Therapeutic interventions that manipulate sleep by targeting these pathways may be a promising approach toward delaying the progression of this incurable disease.
PMID: 33186630
ISSN: 1873-2747
CID: 4675552

Microglial activation in the dorsal striatum participates in anxiety-like behavior in Cyld knockout mice

Han, Yuan-Yuan; Jin, Kai; Pan, Qi-Sheng; Li, Bo; Wu, Zhuo-Qing; Gan, Lin; Yang, Li; Long, Cheng
CYLD lysine 63 deubiquitinase (CYLD), that is mainly involved in immune responses and inflammation, is expressed at high levels in the brain, especially in the dorsal striatum, but its physiological function of CYLD in the brain remains unexplored. The present study investigated the effect of Cyld gene knockout on behavior relevant to the dorsal striatum, such as motor activity and depression-like and anxiety-like behavior. Microglia and the pro-inflammatory cytokines including interleukin (IL)-1 β and tumor necrosis factor (TNF)- α were evaluated in the dorsal striatum to elucidate the underlying mechanism. Cyld knockout (Cyld-/-) mice exhibited anxiety-like behavior, but not motor deficits or depression-like behavior. Microglia were activated and the mRNA levels of IL-1 β and TNF- α were increased in the dorsal striatum of Cyld-/- mice compared to Cyld+/+ mice. The microglial modulator minocycline partially reversed the anxiety-like behavior, microglial activation and increase in IL-1 β and TNF- α mRNA and protein levels in the dorsal striatum of Cyld-/- mice. Collectively, these results suggest that Cyld knockout leading to microglial activation promotes IL-1 β and TNF- α expression and acts as a critical pathway in the pathophysiology of anxiety.
PMID: 32688031
ISSN: 1090-2139
CID: 4704042

Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China

Zheng, Huaguang; Yang, Yi; Chen, Huisheng; Li, Chuanling; Chen, Yangkun; Shi, Fu-Dong; Yang, Li; Cui, Xiaoping; Lu, Zuneng; Liang, Yanling; Cui, Songbiao; Xu, Anding; Wu, Yiqing; Sun, Yaqing; Wang, Yongjun
BACKGROUND AND PURPOSE/OBJECTIVE:Data on the efficacy and safety of alteplase for acute ischaemic stroke (AIS) administered 3-4.5 hours after the onset of stroke symptoms in Chinese patients is limited. We sought to determine whether AIS patients would benefit from thrombolysis with alteplase between 3 and 4.5 hours after the onset of stroke symptoms in a prospective, multicentre, single-arm trial in China. MATERIALS AND METHODS/METHODS:Eligible AIS patients were given 0.9 mg/kg alteplase intravenously. The primary efficacy endpoint was a favourable outcome at 3 months, defined as a score of 0 or 1 on the modified Rankin Scale. Thresholds for the primary efficacy endpoint were determined to be 40% based on the literature review. The primary safety endpoint was symptomatic intracranial haemorrhage (sICH) according to the European Cooperative Acute Stroke Study III (ECASS III) trial definition. Post hoc analysis between this study and the ECASS III trial were compared using the propensity score matching (PSM) method. RESULTS:A total of 120 eligible AIS patients from 11 sites in China received thrombolysis therapy in this study. The median time from onset of symptoms to needle was 3 hours 54 min. The percentage of patients with a favourable outcome was 63.3% (95% CI 54.4 to 71.4), significantly higher than the predefined threshold (p<0.0001). Three patients (2.5%, 95% CI 0.5 to 7.1) had sICH, including two fatal sICH. Six patients died within 3 months after treatment. The post hoc PSM analysis showed a numerically higher rate of the primary efficacy endpoint in this study (63.3%) than the matched placebo arm (56.7%) in the ECASS III trial. CONCLUSIONS:Intravenous alteplase with a standard dose administered between 3 and 4.5 hours after onset of symptoms is effective and safe for Chinese AIS patients. TRIAL REGISTRATION NUMBER/BACKGROUND:NCT02930837.
PMID: 32467323
ISSN: 2059-8696
CID: 4632832